alphaVbeta3 antagonists (Takeda Oncology/Tri-Institutional Therapeutics Discovery Institute)

N/A

Report date: 2025/06/11 10:57:23
NME

Base Information

Drug NamealphaVbeta3 antagonists (Takeda Oncology/Tri-Institutional Therapeutics Discovery Institute)
Drug Alias Nameintegrin alphaVbeta3 antagonists (Takeda Oncology/Tri-Institutional Therapeutics Discovery Institute)TDI-4161TDI-3761
ClassificationSmall molecules
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsBone Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMillennium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMillennium Pharmaceuticals IncTri-Institutional Therapeutics Discovery Institute
Inactive CompaniesN/A
Active IndicationsBone Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A